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Introduction. A promising approach to increase teenager’s 
adherence to immunization against HPV is the administration of 
vaccinations within the school facilities. The Local Health Unit of 
Taranto experienced two different vaccine strategy proposals in 
the twelve-year-olds: the first one was the usual active call strat-
egy in the outpatient clinic, while the second one provided the 
involvement of the schools in the area. The aim of the study is to 
evaluate the results of the proposed vaccination strategies in both 
sexes and in towns of different sizes in order to identify an effec-
tive path for achieving vaccine coverage improvement.
Methods. To estimate the number of anti-HPV vaccine doses 
administered in adolescents of the 2003 cohort, we used the com-
puterized vaccination system data of the Apulia Region. Then, 
once analyzed, the data for anti-HPV vaccine were broken down 
by gender, vaccine strategy and size of the town of residence. 
Analyses performed by using STATA SE 14.
Results. The multiple logistic regression points out that, females 
(OR = 3.2; p < 0.01), living in small towns (OR = 1.3; p < 0.01) 
and school vaccination strategy (OR = 2; p < 0.01) increase the 
likelihood of completing the anti-HPV vaccine cycle in adoles-
cents. The comparative assessment of anti-HPV coverage strate-
gies, suggests that school vaccination has resulted in significantly 
better outcomes than outpatient clinic one, for all the groups con-
sidered (overall 72.3% vs 55.6%).
Conclusions. The involvement of school institutes can define a 
winning organizational model to get a wider adolescent’s adher-
ence to immunization programs, especially in bigger towns. The 
school vaccination strategy could improve anti-HPV vaccine 
adherence also in males, who perceives a lower HPV-related dis-
eases risk than females.
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Summary
Introduction
The human papillomavirus (HPV) infection is the more 
frequent sexually transmitted disease (STD) in the 
world [1]. A meta-analysis conducted on over one mil-
lion women estimated that HPV infection worldwide 
was 11.7%, with a very high peak in the population un-
der the age of 25 [2].
It has been amply described that the role of HPV in de-
termining uterine cervix cancer [3-7] is the fourth cause 
of cancer among women and is responsible for approxi-
mately 275,000 deaths per year [8]. Recently it has de-
veloped a great interest in the relationship between HPV 
infection and some diseases in males, as invasive penile 
cancer. It has been estimated that 30% of the HPV-relat-
ed cancers affects males, corresponding to 17,000 can-
cer cases per year in the European population [9].
The availability of effective vaccines against HPV of-
fers the possibility to decrease morbidity and mortal-
ity rates associated with this pathology: an estimation 
based on 179 countries shows that the vaccination of 12 
years old girls only (for a total of 58 million) would be 
able to prevent 690,000 cancer cases, including 420,000 
deaths [10]. Indeed, since the very first years of the in-
troduction of HPV vaccination, various international 
organizations and scientific associations such as World 
Health Organization (WHO), the Atlanta Centers for 
Disease Control and Prevention (CDC), the American 
Academy of Pediatrics (AAP), the European Centre for 
Disease Prevention and Control (ECDC), recommended 
the administration to 11-12 years old girls with a catch-
up between the age of 13 and 18 [11].
Subsequently, the quadrivalent vaccine demonstrat-
ed its effectiveness in preventing more than 90% of 
HPV-related male genital lesions [12] and different or-
ganizations have extended this indication to teenager 
males [13-15]. However this group is not considered by 
the WHO as a priority, especially in contexts with lim-
ited resources [16]. Currently, with about 120 national 
anti-HPV immunization programs for women [17], 
only USA, Canada, Australia, Austria, Croatia, Liech-
tenstein, Saxony and Czech Republic (the latter only 
for the catch-up) extended to the males the vaccination 
program [13, 18-21]. This is due to the fact that the cost-
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benefit ratio of the anti-HPV vaccination in males varies 
considerably in relation to the duration of the protec-
tive effect induced by the vaccination, to the coverings 
reached in the female population and, of course, the cost 
of the vaccination [22, 23].
A promising approach in order to increase teenagers’ ad-
herence to the anti-HPV immunization is the administra-
tion of the vaccines within school institutes. In Sweden 
and some areas of the United Kingdom, Spain and Aus-
tralia, the coverage of the complete anti-HPV vaccine 
cycle among teenagers reached optimal levels, mainly 
thanks to the school programs [24-28].
In the USA, the school programs in cooperation be-
tween local school system and public health department, 
greatly increased the adherence to different kinds of vac-
cines [29-31].
More than 50% of the European countries providing an 
organized anti-HPV vaccination program, mainly lean 
on school distribution-based strategy  [32], although 
in the literature there are few comparative evaluations 
between schools and outpatient clinic interventions, in 
order to increase the coverage of this vaccination [33]. 
Particularly, the impact of the HPV vaccination program 
offered by schools wasn’t adequately analyzed in rela-
tionship to the context the teenagers live in: the assess-
ment of the vaccination strategy effectiveness should 
consider that, living in a rural area or in a big city can 
change the access to vaccines [34-36].
Since 2007 the Italian Health Authorities recommend-
ed the active and free anti-HPV vaccination offer for 
thne 12 years old girls starting, entrusting the Regions 
with the task of deciding whether to extend the pro-
gram to other categories [37]. The anti-HPV vaccine 
price reduction and the opportunity to reduce the num-
ber of doses needed to confer protection have allowed 
to expand target groups for immunization [23]. On 
2014, Apulia and some other Italian Regions (Ligu-
ria, Sicily, Friuli Venezia Giulia, Molise and Veneto) 
introduced free vaccination for 12 year old males start-
ing with those born in 2003, by using the quadrivalent 
vaccine and overlapping their vaccination schedule to 
the one of the female sex [38]. Currently, the goal to 
reach by the new National Immunization Program is 
the universal anti-HPV vaccination all over the Italian 
Regions [39].
The Local Health Unit of Taranto, experienced two dif-
ferent vaccine strategies: the first one is the usual active 
offer, performed by sending an invitation letter to target 
subjects’ address, and the vaccine administered in the 
vaccine outpatient clinics; the second one involved sec-
ondary schools so that the vaccine was promoted and 
administrated within the school institutes.
In this context, at the end of the first year since the in-
troduction of the universal vaccine, including teenager 
males, the goal of this work is to evaluate the vaccination 
strategies outcomes for both sexes and towns of differ-
ent sizes in order to identify the most efficient path for a 
rapid achievement of optimal coverages.
Materials and methods
The anti-HPV vaccine has been offered to subjects born 
in 2003 by means of two different proposals:
10 vaccination centers, randomly selected, implemented 
the traditional active offer. The family of the target sub-
jects received an invitation letter to go to the vaccination 
center for the immunization. The letter also contained 
information on benefits and risks of anti-HPV vaccina-
tion. This vaccination strategy don’t need a date, but the 
teenagers and their parents can freely access to the out-
patient clinic.
Other 14 vaccine centers involved the secondary schools 
in their jurisdiction. After acquiring the list of the en-
rolled students born in 2003, were organized counselling 
and anti-HPV vaccines promotional meetings with the 
participation of the Local Health Unit’s healthcare pro-
fessionals, the teachers, the students and their parents. 
During the meetings, planned outside of school time, the 
parents provided written consent for the vaccine admin-
istration within the schools. Both doses administration 
was scheduled within the schools during the class time.
In order to estimate the number of anti-HPV doses ad-
ministrated to teenagers born in the period between 
January 1st and December 31st 2003, have been used the 
routine data of annual vaccines updated to December 
31st 2016. The data were collected by infectious disease 
representatives of the Public Health Services and entered 
in the computerized vaccine registry of the Puglia region 
(GIAVA). To calculate the coverage has been used as ref-
erence population of those born in 2003, the one existing 
in the computerized vaccination registry system GIAVA, 
(data updated on December 31st 2016).
The anti-HPV vaccine coverage has been analyzed based 
on gender, vaccine strategy and size of the town. For this 
last feature, was considered the data of the resident pop-
ulation as of January 1st 2016 from the National Institute 
of Statistics, which allowed to classify the districts in 
small and big centers assuming a population of 30,000 
as a cut-off (maximum limit of patients for the general 
medicine functional aggregation in Italy [40]).
Quantitative variables were identified as medians of 
the samples, with the related interquartile range, while 
qualitative variables were expressed as proportions with 
a 95% confidence interval. Mann-Whitney rank-sum test 
has been used for the median values comparison, while 
the chi-squared test has been used for the proportions 
comparison.
We assessed the possible correlations among the ex-
plored variables by defining double-entry contingency 
tables and calculating Chi-Square (Chi2) and Odds Ra-
tio (OR) with 95% CIs. The variables considered in uni-
variate analyses were evaluated in a logistic regression 
model to study the relationship between the vaccination 
coverage and the explanatory variables, while adjusting 
for confounding factors and effect modification if need-
ed. OR with 95% CI was used to evaluate the strength 
of an association. The significance level was considered 
when p < 0.05. Analyses were performed by using STA-
TA SE 14 for Mac OS. 
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Results
In the Local Health Unit of Taranto, there are 5720 sub-
jects belonging to the 2003 cohort. The sample distribu-
tion by gender, town size and vaccination strategy it’s 
quite uniform as shown in Table I.
The complete cycle administration coverage of the anti-
HPV vaccine for the 2003 cohort it’s 63% (n = 3603; 
95% CI  =  61.7-64.2%). The interval median between 
the 2 doses administration for those teenagers who com-
pleted the cycle is 194 days (p25-p75 = 184-225).
In the univariate analysis, the female sex, living in a 
small town and the school vaccine strategy increase the 
likelihood of anti-HPV vaccine cycle completion for 
teenagers (Tab. II). 
The multiple logistic regression confirms the existence 
of these connections, that are more evident for the female 
sex (OR = 3.2; 95% CI = 2.8–3.5; p << 0,01) and for the 
school strategy (OR = 2; 95% CI = 1.8–2.3; p << 0,01), 
rather than small towns (OR = 1.3; 95% CI = 1.1–1.4; 
p << 0,01) (Tab. III).
The coverage for the teenagers immunized at school is 
84.5% (n = 1089/1289; 95% CI = 82.5-86.5%) for the 
females and 59.7% (n = 741/1241; 95% CI = 57-62.4%) 
for the males (Fig. 1).
By considering the town size as a discriminating pa-
rameter, the coverage reached by school vaccination is 
71.7% (n = 1066/1487; 95% CI = 69.4-74%) in the small 
towns and 73.2% (n = 764/1043; 95% CI = 70.6-75.9%) 
in the big ones.
The comparative evaluation of the coverage, by con-
sidering the different vaccination strategies shows that 
the school vaccination leads to significantly better re-
sults than the outpatient clinic one, for all the considered 
groups (Fig. 1).
The proportion of subjects who did not completed the 
vaccine cycle, after receiving the first dose, is 15% of 
those vaccinated in the outpatient clinics (n = 314/2087; 
95% CI  =  13.5-16.7%) and 8.5% of those immunized 
at school (n=169/1999; 95% CI = 7.3-9.8%); that is a 
significant difference according to the Chi square test 
(χ2 = 42.6; p << 0.01).
The median of the interval time between the two doses, 
for those who completed the cycle, is 184 days (p25-
p75 = 183-209) for the vaccines administrated in school, 
and 217 (p25-p75 = 196-259) for the vaccines adminis-
trated in outpatient clinic; that is a significant difference 
according to the Mann-Whitney rank sum test (p < 0.01).
Discussion and conclusions
After one year since the introduction of the global im-
munization, the comparative analysis between the 
school and the outpatient anti-HPV immunization pro-
grams gives interesting and useful information to keep in 
mind for setting the most effective vaccination strategy.
The anti-HPV school vaccination for the 12 year olds 
in the Taranto Local Health Unit has been far more ef-
fective than the outpatient one, leading to the best over-
all results. The gap between the coverage, got by the 
two strategies is 16% for both genders. This result it’s 
aligned with the data existing in the literature, confirm-
ing that school vaccination is associated to better cover-
age [41], and clearly showing that school institutes could 
Tab. I. 2003 cohort teenagers characteristics. Taranto Local Health 










Tab. II. Univariate analysis about determinants of HPV vaccination, Taranto Local Health Unit, 2003 cohort (n = 5720).
Gender N % OR (95% CI) χ2 P value
Female 2164 60.1% 3.1 (2.7-3.4) 392.8 0.00
Town size
Small 1645 45.7% 1.5 (1.3-1.7) 52.6 0.00
Vaccine strategy
School 1830 50.8% 2.1 (1.9-2.3) 169.9 0.00
Tab. III. Multivariate analysis about determinants of HPV vaccination, Taranto Local Health Unit, 2003 cohort (n = 5720).
Gender z OR (95% CI) P value
Female 19.6 3.2 (2.8-3.5) 0.00
District size
Small 3.7 1.3 (1.1-1.4) 0.00
Vaccine strategy
School 11.5 2 (1.8-2.3) 0.00
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be the key to getting greater participation to teenage vac-
cination programs.
That’s especially important for males, since the cover-
age it’s significantly lower than the one recorded for fe-
males. The males, according to other previous studies, 
are in fact associated to a lower chance of completion 
of the anti-HPV cycle [42]. The main limiting reason 
which adversely affects the prevention campaign against 
the HPV-infection in men, it could be the lack of risk 
perception connected to this STD [43]. That’s why the 
school vaccination, by means of a more direct and ef-
fective counselling activity, could be an important pro-
motional way to the immunization and adhesion to the 
anti-HPV vaccine among the teenagers  [44]. Meetings 
with healthcare professionals about vaccine counselling 
represents a better approach compared to the traditional 
invitation letter to the outpatient clinic and allows to 
show in a thorough way the benefits of vaccination, es-
pecially for the males.
The impact of the anti-HPV school administration strat-
egy it’s particularly evident in towns with more than 
30,000 people, where there is an increase in coverage 
of 20.5% compared to the outpatient vaccination. Right 
in those contexts in which the study found the greatest 
difficulties in reaching the target population of the vac-
cine offer, the school proposal has been undoubtedly ef-
fective. A possible interpretation may be the greater ac-
cessibility of school vaccination, this hypothesis is also 
supported by other data such as the reduced number of 
teenagers who didn’t complete the vaccine cycle after 
receiving the first dosage and the median interval short-
ening between the two doses. 
It should be underlined that the reported coverage esti-
mate for school vaccination, also include the catch-up 
doses administrated in outpatient clinics to those school 
children who were absentees when the school vaccina-
tion was scheduled. In addition, those who were already 
privately vaccinated before 2014, were excluded from 
the calculation. 
To set up a school vaccination campaign needs a consid-
erable organizational effort. First, the vaccinations must 
be performed in compliance with the best safety stand-
ards: healthcare professionals must have Pediatric Basic 
Life Support and Defibrillation (P-BLSD) certifications, 
as well as a portable pharmacological and instrumental 
kit for emergencies. In the future, it will be important the 
cooperation with the schools to set up permanent out-
patient clinics for all the students’ health needs, includ-
ing vaccinations. Moreover it’s proper to allow real time 
access to the computerized vaccine registry, data entry 
from a laptop and a dedicated network connection.
Anyway, the school is the best place to perform health 
promotion and collective health education programs 
against vaccine-preventable diseases. Some countries 
included the school vaccination strategy into a wider 
school-based health approach, thus improving the im-
pact of those interventions [45]. 
In this regard, integrating the health promotion and 
school vaccination programs seems to be the most sus-
tainable solution also with regard to human resources 
management, especially if it’s associated with teacher’s 
involvement. Furthermore the healthcare professionals in 
schools could administrate much more vaccinations than 
Fig. 1. Coverage for anti-HPV complete cycle. Taranto Local Health Unit, 2003 cohort, by gender and town size.
   Small towns                          Big towns                            Male sex                            Female sex                               Total   
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in the outpatient clinics, since they could save time by 
doing counselling vaccination in a single group session.
The Taranto Local Health Unit experience suggests that 
the school is the ideal context to get the wider adherence 
to the anti-HPV immunization programs. The most im-
portant factors for the success of the school-based vacci-
nation strategy are the “good” relationships between the 
Local Health Unit and the Local School management, 
the working skills improvement and the communication 
with the students and their parents. 
If the application of the aforementioned organizational 
model to different contexts and wider samples will con-
firm the outcomes, it could be adopted as a regional or 
national strategic plan able to oppose the hesitancy and 
stimulate resilience phenomena to vaccination.
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